S. Ong

发表

Identification of cis-Acting Elements and Splicing Factors Involved in the Regulation of BIM Pre-mRNA Splicing

X. Roca, W. Juan, S. Ong, 2014, PloS one.

Identification of drugs for leukaemia differentiation therapy by network pharmacology

Eleni G. Christodoulou, E. Petretto, E. Christodoulou, 2019, bioRxiv.

This information is current as Activity in T Cells Responding to IL-2 S-Phase Entry and Maintains S6 Kinase Protein/Caspase-8-Signaling Axis Promotes A Fas-Associated Death Domain

Y. Kanno, R. Siegel, M. Walsh, 2013 .

A Fas-Associated Death Domain Protein/Caspase-8-Signaling Axis Promotes S-Phase Entry and Maintains S6 Kinase Activity in T Cells Responding to IL-21

Y. Kanno, R. Siegel, S. Ramos, 2007, The Journal of Immunology.

The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

P. Ng, Asif Javed, W. Sung, 2015 .

Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.

A. Poulsen, J. Cherian, Boping Liu, 2016, Journal of medicinal chemistry.

Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.

S. Yano, K. Fukuda, S. Takeuchi, 2020, The journal of medical investigation : JMI.

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia

C. Chuah, D. Huang, S. Khaw, 2013, Oncotarget.

FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.

G. Giaccone, J. Minna, I. Wistuba, 1997, Cancer research.

Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma.

M. L. Le Beau, S. Ong, 1998, Seminars in oncology.

Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance

Min Zhang, B. Druker, H. Fan, 2008, Molecular and Cellular Biology.

Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines

J. Minna, M. L. Le Beau, T. McKeithan, 1997, Genes, chromosomes & cancer.

BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients

C. Chuah, J. Allen, H. Than, 2018, Leukemia & lymphoma.

Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

L. Poellinger, C. Chuah, Soo-Yong Tan, 2011, Blood.

Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

S. Ong, J. Ng, 2022, Current Hematologic Malignancy Reports.

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

C. Chuah, T. Ko, S. Ong, 2014, Oncotarget.

A novel Bcr-Abl–mTOR–eIF4A axis regulates IRES-mediated translation of LEF-1

Min Zhang, B. Semler, C. Chuah, 2014, Open Biology.

A novel Bcr-Abl – mTOR – eIF 4 A axis regulates IRES-mediated translation of LEF-1 Becky

B. Semler, C. Chuah, M. Waterman, 2014 .

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

C. Chuah, T. Ko, S. Ong, 2017, PloS one.

RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data

Quy Xiao Xuan Lin, N. A. Rayan, S. Prabhakar, 2021, Nucleic acids research.

Robust clustering and interpretation of scRNA-seq data using reference component analysis

Florian Schmidt, Shyam Prabhakar, Bobby Ranjan, 2021, bioRxiv.

Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches

X. Roca, D. Bergstrom, W. Juan, 2018, Scientific Reports.

Knock-In of a 25-Kilobase Pair BAC-Derived Donor Molecule by Traditional and CRISPR/Cas9-Stimulated Homologous Recombination

X. Roca, D. Bergstrom, W. Juan, 2016, bioRxiv.

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.

P. Ng, Asif Javed, Y. Sia, 2020, Blood.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Jing Chen, Marina Konopleva, Yi Liu, 2010, Nature Medicine.

The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.

W. Juan, S. Ong, 2012, Progress in molecular biology and translational science.

Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.

J. Melo, C. Walsh, S. Ong, 2003, Cancer research.

Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia

M. Tschan, M. Fey, A. Tobler, 1999, Oncogene.

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

S. Branford, S. Ong, V. Krishnan, 2021, Haematologica.

A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation

D. Saadat, M. Zhang, J. Fruehauf, 2007, Oncogene.

Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2.

R. Espinosa, M. L. Le Beau, R. McCarroll, 1996, Genomics.

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

Jun Liu, F. Rigo, X. Roca, 2017, Oncotarget.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Jae Cheol Lee, Jih-Hsiang Lee, F. Siddiqui, 2017, Oncotarget.

Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia

A. Yeoh, L. Bendall, Su-Lin Lim, 2014, PloS one.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

M. Nöthen, N. Nagarajan, T. Wong, 2012, Nature Medicine.

Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance

C. Chuah, H. Than, S. Ong, 2016 .

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

M. Ando, Y. Hasegawa, S. Yano, 2019, Cancer science.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

S. Mustjoki, B. Druker, J. Cortes, 2019, Leukemia.

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer

X. Roca, S. Yano, K. Fukuda, 2016, Clinical Cancer Research.

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors

P. Dakle, W. Chng, V. Madan, 2022, International journal of molecular sciences.

SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia

A. Krainer, C. Chuah, S. Rozen, 2020, Leukemia.

Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function

D. Fruman, C. Chuah, H. Fan, 2013, Proceedings of the National Academy of Sciences.

The arginase inhibitor Nω−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target

Chin Yee Tan, T. Suda, C. Chuah, 2018, PloS one.

Heritable resistance to tyrosine kinase inhibitors.

S. Ong, 2014, Clinical advances in hematology & oncology : H&O.

Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia

Asif Javed, A. Hillmer, C. Chuah, 2022, Leukemia.

Advances in Brief Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin 1

J. Melo, C. Walsh, S. Ong, 2003 .

Leukemia Cells via the Mammalian Target of Rapamycin Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Bcr-Abl Kinase Modulates the Translation Regulators

J. Melo, C. Walsh, S. Ong, 2003 .

Chin Yee Tan, K. Lee, S. Ong, 2018, PloS one.

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia.

John F. Ouyang, T. Tan, N. A. Rayan, 2022, Blood.

Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia

A. Hillmer, C. Chuah, W. Lim, 2014, Nature Network Boston.